AgeChem Venture Fund
VC Fund
Montréal, Canada
AgeChem Venture Fund is a VC fund in Montréal focused on Biotechnology and Biopharma. The AgeChem Fund L.P. currently has $65 million under management and is seeking to invest in companies developing therapeutics targeting age-related diseases. Principally, AgeChem wishes to build a portfolio of Companies developing novel therapeutics to treat metabolic disorders (e.g. diabetes, obesity), cardiovascular diseases, cancers, diseasesof the central nervous system (e.g. Alzheimer, Parkinson, insomnia), inflammatory diseases (e.g. rheumatoid arthritis, psoriasis), ophthalmic diseases and numerous other age-related diseases.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries AgeChem Venture Fund invests in
Stages AgeChem Venture Fund invests in
Countries AgeChem Venture Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Martial Lacroix
|
|||
Investment Focus
Industry
- Biotechnology 2 (40%)
- Biopharma 1 (20%)
- Health Care 1 (20%)
- Therapeutics 1 (20%)
- Pharmaceutical 1 (20%)
Stage
- Series B 2 (40%)
- Series A 1 (20%)
- Series D 1 (20%)
- Funding Round 1 (20%)
Country
- Canada 1 (20%)
- United States 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Martial Lacroix
General Partner
|
General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sorbent Therapeutics
|
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois. | Series D / May 15, 2014 | |
Alethia BioTherapeutics
|
Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $4.7M / Series B / Nov 02, 2012 | |
|
Sorbent Therapeutics
|
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois. | $21.8M / Series B / Sep 13, 2010 | |
|
Alethia BioTherapeutics
|
Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $9.2M / Series A / Sep 07, 2010 | |
Advitech
|
Advitech is a life science and technology company with the mission to discover and commercialize patented, scientifically supported natural health products. Effective and safe, these products target immune system disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex (R) for the treatment of mild to moderatepsoriasis. Advitech has developed a research program to develop new applications in the field of wound healing. This development program stems from the two technological platforms XP-828L and IM. | $2.5M / Nov 26, 2009 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does AgeChem Venture Fund invest in?
AgeChem Venture Fund invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact AgeChem Venture Fund?
Public channels for AgeChem Venture Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AgeChem Venture Fund?
The team at AgeChem Venture Fund includes Martial Lacroix (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
